

# Glasdegib (Daurismo) Criteria for Use May 2020

VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives

*The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.*

The Product Information should be consulted for detailed prescribing information.

See the VA National PBM-MAP-VPE Monograph on this drug at [www.pbm.va.gov](http://www.pbm.va.gov) or <http://vaww.pbm.va.gov> for further information.

## Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive Glasdegib:

- Unable to comply with recommended laboratory monitoring
- Baseline QTc > 470 msec
- Severe renal impairment (<30 mL/min) – has not been studied
- Severe hepatic impairment (LFT>3x ULN) – has not been studied
- Pregnancy (i.e. known pregnancy or positive pregnancy test)
- Breastfeeding

## Inclusion Criteria

ALL of the following must be fulfilled in order to meet criteria:

- Prescriber is a VA or VA Community Care hematology/oncology provider
- Goals of care and role of Palliative Care consult have been discussed and documented
- ECOG performance status 0-2
- New diagnosis of previously untreated, acute myeloid leukemia (AML)
- Not eligible (or declines) intensive induction chemotherapy
- No actionable mutations (e.g. FLT3 mutation)
- Able to receive concurrent low-dose subcutaneous cytarabine
- Medication profile reviewed for concomitant CYP3A inducers, inhibitors and QTc prolonging drugs for glasdegib dose adjustment
- For female patients of child-bearing potential: provided counseling on effective contraception, and risk vs. benefit of treatment. Continue contraception for at least 30 days after final dose.
- For male patients with partners of child-bearing potential: provided counseling on effective contraception and potential risks vs. benefit of treatment. Continue contraception for at least 30 days after final dose.

Updated version may be found at [PBM INTERNET](#) or [PBM INTRANET](#)